• LGR5 is expressed, both in vitro and in vivo, by numerous human cancers, including colorectal, ovarian, gastric, brain, and pancreatic cancer.

• LGR5-targeting CAR-T cells effectively kill LGR5-expressing cancer cells in in vitro cytotoxicity assays and display significant anti-tumor activity in vivo in a subcutaneous human colorectal cancer xenograft mouse model.

• LGR5-targeting CAR-T cells that induce primary tumour clearance confer complete protection against a secondary tumour challenge.

• In vivo spatiotemporal distribution and repeated dosing studies demonstrate that LGR5-targeting CAR-T cells do not persist in off-target organs and are safe and well-tolerated under the conditions tested.

• These studies allowed selection of a clinical candidate (CNA3103) for a Phase 1/2a clinical trial in patients with advanced colorectal cancer.
  

ADELAIDE, Australia, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Carina Biotech (Carina), a cell therapy immuno-oncology company, announced a poster presentation from preclinical studies of its LGR5-targeting CAR-T platform in colorectal cancer at the 8th CAR-TCR Summit that will take place in Boston, Massachusetts from 29 August – 1 September 2023.

“We are thrilled to continue to share our preclinical data related to our LRG-5 targeted autologous CAR-T platform in colorectal cancer at the upcoming 8th CAR-TCR Summit,” said Deborah Rathjen, PhD, Carina’s Chief Executive Officer. “We are encouraged by the data evidenced in our preclinical studies, further supporting our LGR5 CAR-T cell candidate, CNA3103. These data were crucial in the selection of CNA3103 for a Phase 1/2a clinical trial in patients with advanced colorectal cancer and we are pleased to report that patient screening has commenced.”

Poster Presentation Details

Title: LGR5-targeting CAR-T cells – The road to the clinic.
Lead Author: Deborah A. Rathjen CEO, Carina Biotech Limited, Adelaide, South Australia,
Session Date and Time: Thursday 31 August 2023 from 3:30 PM ET – 4:30 PM ET
Location: Exhibition Hall D
Poster Board Number: 131

For more information about LGR5 and Carina Biotech’s clinical pipeline visit www.carinabiotech.com.

About Carina Biotech

Immuno-oncology company Carina Biotech is developing CAR-T and other adoptive cell therapies for the treatment of solid cancers. In addition to its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer, Carina has a deep pipeline of CAR-T programs.

Using its proprietary chemokine receptor platform, Carina aims to improve traffic to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects.

Carina also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell attributes, capable of delivering robust “serial-killing” CAR-T cells to patients.

For more information please contact:

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.